Gyre Therapeutics (GYRE) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- $0.03
- EPS estimate
- $0.05
- EPS surprise
- −35.76%
- Revenue surprise
- −7.18%
- Revenue
- $30.6M
- Revenue estimate
- $32.9M
- Reported
- Nov 7, 2025
Gyre Therapeutics reported Q3 2025 results on November 7, 2025, the latest quarter in the table. EPS was $0.03, 35.76% below the $0.05 estimate. Revenue of $30.6 million missed the $32.9 million consensus by 7.18%. Against Q3 2024, EPS rose from $0.01 and revenue grew 20% from $25.5 million. Q3 2025 revenue was the highest in the table.
The record skips several quarters in 2022 and 2023, and the per-share figures before 2024 are on a very different scale. From 2020 to 2023, Gyre posted losses of $1.05 to $19.05 per share in every quarter shown apart from a $24.60 profit in Q2 2022, and revenue was mostly below $2.5 million. Since 2024, EPS has been between $0.00 and $0.03, with revenue of $22.1 million to $30.6 million. The first three quarters of 2025 brought $79.5 million in revenue, about 2% more than a year earlier. EPS fell short of the estimate in each of the last four quarters.
The table does not yet include Q4 2025 or any 2026 quarter. Past Q4 reports came between late February and the end of March. The next figures added will show whether the small profits seen since 2024 continued.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 7, 2025 | $0.05 | $0.03 | −35.76% | $30.6M | SEC |
| Q2 2025 | Aug 11, 2025 | $0.03 | $0.00 | −100.00% | $26.8M | SEC |
| Q1 2025 | May 9, 2025 | $0.03 | $0.00 | −100.00% | $22.1M | SEC |
| Q4 2024 | Feb 18, 2025 | $0.04 | $0.00 | −100.00% | $27.9M | SEC |
| Q3 2024 | Nov 13, 2024 | $0.00 | $0.01 | +0.00% | $25.5M | SEC |
| Q2 2024 | Aug 13, 2024 | $0.00 | $0.01 | +0.00% | $25.2M | SEC |
| Q1 2024 | May 9, 2024 | $0.00 | $0.03 | +0.00% | $27.2M | SEC |
| Q2 2023 | Aug 14, 2023 | −$1.05 | −$1.05 | +0.00% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$1.58 | −$19.05 | −1109.52% | $0.00 | SEC |
| Q2 2022 | Aug 15, 2022 | −$3.68 | $24.60 | +769.39% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$6.85 | −$6.90 | −0.73% | $794,000.00 | SEC |
| Q4 2021 | Mar 31, 2022 | −$8.81 | −$9.75 | −10.64% | $2.4M | SEC |
| Q3 2021 | Nov 12, 2021 | −$9.90 | −$12.00 | −21.21% | $2.3M | SEC |
| Q2 2021 | Aug 5, 2021 | −$10.43 | −$9.60 | +7.91% | $1.1M | SEC |
| Q1 2021 | May 6, 2021 | −$8.66 | −$11.85 | −36.80% | $1.5M | SEC |
| Q4 2020 | Mar 4, 2021 | −$12.94 | −$12.90 | +0.29% | $2.0M | SEC |
| Q3 2020 | Nov 5, 2020 | −$12.10 | −$10.95 | +9.50% | $893,000.00 | SEC |
| Q2 2020 | Aug 6, 2020 | −$12.94 | −$14.40 | −11.30% | $1.7M | SEC |
| Q1 2020 | May 11, 2020 | −$5.48 | −$4.20 | +23.29% | $16.4M | — |
Quarterly revenue
Frequently asked questions
When did Gyre Therapeutics (GYRE) last report earnings?
Gyre Therapeutics last reported on Nov 7, 2025, covering fiscal Q3 2025.
Did GYRE beat earnings estimates?
No. Gyre Therapeutics reported EPS of $0.03 for Q3 2025 against a $0.05 estimate — a 35.76% miss.
How much revenue did GYRE report last quarter?
Gyre Therapeutics reported $30.6M in revenue for Q3 2025, against a consensus estimate of $32.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.